About EVerZom

The startup has developed a GMP-compliant platform for manufacturing extracellular vesicles using proprietary technology tailored for pharmaceutical research. These vesicles possess protective and reparative properties, providing a therapeutic solution for organ failure by restoring function and homeostasis.

```xml <problem> Current cell therapies for tissue regeneration and related diseases face limitations, including risks of uncontrolled cell replication, differentiation, vascular occlusion, and supply chain challenges. Traditional methods of exosome production also struggle with scalability and cost-effectiveness, hindering widespread clinical application. </problem> <solution> EVerZom is developing exosome-based therapeutics for regenerative medicine, offering a safer and more convenient alternative to cell therapies. The company has developed a GMP-compliant platform that addresses the challenges of exosome manufacturing, enabling high-yield, large-scale production of both naive and engineered exosomes. Their innovation platform covers the entire value chain, including cell sourcing, exosome generation using a patented mechanical stimulation method, exosome loading via turbuloporation, and formulation to enhance biodistribution and bioavailability. EVerZom is developing a pipeline of proprietary products, including therapies for digestive tissue healing and organ regeneration, and is open to co-development partnerships in other therapeutic areas. </solution> <features> - Patented method for high-yield exosome production using controlled mechanical stimulation in 3D bioreactors - Turbuloporation technology for active exosome engineering, enabling the loading of RNA, proteins, or chemotherapeutic agents while preserving exosome properties - Thermoresponsive hydrogel formulation for local administration, improving exosome retention at the injury site - Capability to modify mother cells to release exosomes overexpressing specific RNAs or proteins - Platform designed for GMP compliance and scalability to accelerate clinical transfer and commercialization - Expertise in both naive and engineered exosome-based therapies </features> <target_audience> The primary target audience includes pharmaceutical companies, biotech firms, and research institutions focused on regenerative medicine, drug delivery, and the development of exosome-based therapeutics. </target_audience> ```

What does EVerZom do?

Where is EVerZom located?

EVerZom is based in Paris, France.

When was EVerZom founded?

EVerZom was founded in 2019.

How much funding has EVerZom raised?

EVerZom has raised 950000.

Location

Paris, France

Founded

2019

Funding

950000

Employees

17 employees

Major Investors

European Innovation Council

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

EVerZom

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

everzom.com 3K+

Crunchbase

Founded 2019 – Paris, France

Funding

Estimated Funding

$500K+

Major Investors

European Innovation Council

Team (15+)

No team information available.

Company Description

Problem

Current cell therapies for tissue regeneration and related diseases face limitations, including risks of uncontrolled cell replication, differentiation, vascular occlusion, and supply chain challenges. Traditional methods of exosome production also struggle with scalability and cost-effectiveness, hindering widespread clinical application.

Solution

EVerZom is developing exosome-based therapeutics for regenerative medicine, offering a safer and more convenient alternative to cell therapies. The company has developed a GMP-compliant platform that addresses the challenges of exosome manufacturing, enabling high-yield, large-scale production of both naive and engineered exosomes. Their innovation platform covers the entire value chain, including cell sourcing, exosome generation using a patented mechanical stimulation method, exosome loading via turbuloporation, and formulation to enhance biodistribution and bioavailability. EVerZom is developing a pipeline of proprietary products, including therapies for digestive tissue healing and organ regeneration, and is open to co-development partnerships in other therapeutic areas.

Features

Patented method for high-yield exosome production using controlled mechanical stimulation in 3D bioreactors

Turbuloporation technology for active exosome engineering, enabling the loading of RNA, proteins, or chemotherapeutic agents while preserving exosome properties

Thermoresponsive hydrogel formulation for local administration, improving exosome retention at the injury site

Capability to modify mother cells to release exosomes overexpressing specific RNAs or proteins

Platform designed for GMP compliance and scalability to accelerate clinical transfer and commercialization

Expertise in both naive and engineered exosome-based therapies

Target Audience

The primary target audience includes pharmaceutical companies, biotech firms, and research institutions focused on regenerative medicine, drug delivery, and the development of exosome-based therapeutics.